The expected goal of this partnership is to have an FDA approved intranasal naloxone solution for the reversal of opioid overdoses that can be brought to market within 12 to 18 months.Naloxone is a lifesaving drug used in an emergency to treat patients who have overdosed on opioids such as heroin or oxycodone.